CDK2 and neuroblastoma: Taken together, our results suggest that CDK2 and CDK9 are potential therapeutic targets in NB and that novel small molecule CDK inhibitors like dinaciclib, alone or in combination with chemotherapeutic agents, should be developed for patients with NB.